Further CelGro® nerve clinical trial data from all patients at 12 months, page-62

Early days for a company like Orthocell, approvals, partnerships, commercialisation don’t happen overnight. The Aussie market is like a dead fish floating down the river, no one likes changes. The US market is a lot different, where they embrace technologies and put them to market, the Aussie market will catch on but only when when this thing takes off in America. Striate+ is partnered up for training purposes and marketing, this should lead to a commercial partner soon enough, this year I doubt it, but 2022 for sure. Remember training and marketing is a essential for any biotech trying to crack the market